Venomyx Therapeutics

Venomyx Therapeutics

EpiPen for snakebites: the antivenom of tomorrow!

Print
View on Wefunder
Security Type
SAFE
Categories
Other
Min Investment
$15
Offering Date
February 23, 2019
Expected Close Date
March 31, 2019
Target Raise
$50.00K-$750.00K
Deal Notes

First $75K investors of this fundraise will invest in a SAFE with a $4M valuation cap and 15% discount.

$25K+ pro rata right threshold

Company Description

We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum antivenom for snakebites. Conventional antivenom is outdated: it's expensive, labor-intensive, works for a single species of snake, can only be administered in a hospital, must be kept cold, and has a host of negative side effects for the patient. Our first product, Vipax, elegantly solves these problems while being cheaper to produce.

Perks

$5,000+ Get a limited offer Venomyx T-shirt
$25,000+ We'll invite you to fly out to our lab and give you a tour of our facility and processes.

Use of Proceeds

Intermediary Fee: 5%

Manufacturing of Product: 45%

Pre-Clinical Testing: 50%

Management Team / Advisory Board Bios

Daniel Dempsey - Founder & CEO
Extensive background in developing antibody drugs and bringing to market. MS Biomedical from UCSD.

Deepankar Roy - Co-founder & COO
Expertise in antibody engineering, Genentech. PhD in Biochem and Molecular Bio from USC.

Deal Notes

First $75K investors of this fundraise will invest in a SAFE with a $4M valuation cap and 15% discount.

$25K+ pro rata right threshold

Amount Raised : $270,094
Reveal the Score by Voting
＿
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
ⓘ
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
ⓘ
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
ⓘ
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
ⓘ
The value of the company compared to similar companies raising money from investors.
Valuation

Security Description

A SAFE is an agreement between you—the investor—and the company in which the company promises to give you a future equity stake based on the amount you invested. It also involves some kind of a triggering event that must take place in order for you to get your future equity stake. Be careful as you may only get equity if a particular event is triggered.

Research Reports

No reports have been submitted

Become a Reporter
Read Our Research Disclaimer

0 Comments

Post Comment